Related Experiment Video
Updated: Apr 22, 2026

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders
Published on: August 18, 2023
Long-term and short-term effects of insomnia in cancer and effective interventions
Mellar P Davis1, Harold W Goforth
1From the *Cleveland Clinic Lerner School of Medicine, Case Western Reserve University; and †Palliative Medicine and Supportive Oncology Services, Division of Solid Tumor, Taussig Cancer Institute, and ‡Neurological Institute, Department of Psychiatry and Psychology, The Cleveland Clinic, Cleveland, OH.
Abstract:
Sleep disorders and insomnia are more prevalent in patients with cancer than in the normal population. Sleep disorders consist of delayed sleep latency, waking episodes after sleep onset, unrefreshing sleep, reduced quality of sleep, and reduced sleep efficiency. Sleep disorders cluster with pain, fatigue, depression, anxiety, and vasomotor symptoms, depending on stage of disease, treatment, and comorbidities. Premorbid sleep problems and shift work have been associated with a higher prevalence of cancer; in fact, shift work has been labeled a carcinogen. Treatment for insomnia includes cognitive behavioral therapy with sleep hygiene, bright-light therapy, exercise, yoga, melatonin, and hypnotic medications. Unfortunately, there are few randomized trials in cancer-related sleep disorders such that most recommendations particularly for hypnotics are based on treatment for primary insomnia. In this article, insomnia is reviewed as a predisposing factor to cancer, prior to and during treatment, in cancer survivorship and in advanced cancer. Recommendations for treatment are based on low-quality evidence but are also reviewed.
Related Concept Videos
Insomnia
Multiple factors contribute...
Management of Insomnia
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Cancer Survival Analysis
Psychoneuroimmunology: Diabetes and Cancer
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...